Quality improvement program improves depression screening among cancer patients
Depression screening among cancer patients improved by 40 percent to cover more than 90 percent of patients under a quality improvement program launched by a multidisciplinary team at UT Southwestern Medical Center and Southwestern Health Resources.
Cancer patients with depression are at an increased risk of mortality and suicide compared with those without depression. Although rates vary based on cancer type and stage, depression is estimated to affect 10 to 30 percent of patients with cancer compared with 7 to 8 percent of adults without a diagnosis or history of cancer, and impact both men and women equally.
Texas hospital uses quality model to increase depression screenings for cancer patients
Getty Images
UT Southwestern Medical Center in North Texas reports that it increased depression screenings of oncology patients by 44% in a quality improvement project.
More than 90% of the hospital s oncology patients received a screening and follow-up care, or about 14,000 patients. The findings were published Friday in the Journal for Healthcare Quality from the National Association for Healthcare Quality. Identifying those with depressive symptoms through earlier detection, diagnosis and treatment can greatly improve the quality of life for these patients and their families, and prevent minor symptoms from progressing to severe psychopathology and potential self-harm, said Dr. Jason Fish, chief medical officer at Southwestern Health Resource, a clinically integrated healthcare network with the medical center as its care provider.
Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment
News provided by
Share this article
SHANGHAI and HONG KONG, April 28, 2021 /PRNewswire/ With the official release and implementation of
the Overall Plan for the Construction of Hainan Free Trade Port, patient can now access global innovative medicines in mainland China. Recently,
the global first-in-class selective inhibitor of nuclear export (SINE) compound, selinexor (XPOVIO®), was prescribed for the first time in mainland China at the Boao Super Hospital in Boao Lecheng Pilot Zone and has been authorized to be expanded beyond the Pilot Zone for the outpatient treatment of relapsed or refractory multiple myeloma (rrMM). Prescribing selinexor for the first time in China is a significant milestone in changing the hematological cancer treatment landscape in the country as it allows Chinese
(1) DJ EQS-News: Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment EQS-News / 29/04/2021 / 11:36 UTC+8 Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment With the official release and implementation of the Overall Plan for the Construction of Hainan Free Trade Port, patient can now access global innovative medicines in mainland China. Recently, the global first-in-class selective inhibitor of nuclear export (SINE) compound, selinexor (XPOVIO(R)), was prescribed for the first time in mainland China at the Boao Super Hospital in Boao Lecheng Pilot Zone and has been authorized to be expanded beyond the Pilot Zone for the outpatient treatment of relapsed or refractory multiple myeloma (rrMM). Prescribing selinex